Entera Bio (ENTX)

Executive Summary

Entera Bio is a clinical-stage biopharmaceutical company specializing in oral delivery of peptides and proteins via its proprietary N-Tab® platform. The platform aims to replace injectable biologics with convenient oral tablets, addressing high unmet needs in metabolic bone diseases and obesity. Lead programs include EB612 (oral PTH 1-34) for hypoparathyroidism and EBP05 for osteoporosis, both of which have completed Phase 2 trials demonstrating proof-of-concept. The company benefits from a strong intellectual property position and has shown bioavailability and safety in multiple studies. With a market cap of ~$65M, Entera is positioned for value inflection as it prepares for pivotal trials and potential partnerships. However, the stock remains speculative given early-stage cash flows and dependence on regulatory and clinical execution.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 3 trial for EBP05 in hypoparathyroidism80% success
• H1 2027Licensing or partnership deal for N-Tab platform in obesity or other indications50% success
• Q2 2027FDA meeting feedback on clinical path for oral PTH product70% success